106P Impact of molecular alterations in advanced biliary tract cancer (BTC) patients (pts) treated with cisplatin, gemcitabine, durvalumab (CGD): A large global study
F. Lo Prinzi(Università Campus Bio-Medico), A. Casadei Gardini(IRCCS Ospedale San Raffaele), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Tiziana Pressiani(IRCCS Humanitas Research Hospital), Oluseyi Abidoye(Mayo Clinic), Anna Saborowski(Medizinische Hochschule Hannover), L. Antonuzzo(Azienda Ospedaliero-Universitaria Careggi), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Jessica Lucchetti(Campus Bio Medico University Hospital), Mario Domenico Rizzato(University of Padua), M. Rimini(Vita-Salute San Raffaele University), Federico Rossari(Vita-Salute San Raffaele University), Lorenza Rimassa(Humanitas University), C. Vivaldi(Azienda Ospedaliera Universitaria Pisana), Frederik Peeters, Jin Won Kim(Seoul National University Bundang Hospital), Tatsunari SATAKE(National Cancer Center Hospital East), Silvia Camera(Vita-Salute San Raffaele University)
Cited by 0
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k